



## Targeted Therapies/Targetable Molecules for Treatment of Cancer and Diseases That Could Predispose to Cancer

Guest Editors:

**Dr. Prema Robinson**

Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

**Dr. Miguel Muñoz**

1. Pediatric Intensive Care United, Virgen del Rocío University Hospital, 41013 Seville, Spain  
2. Research Laboratory on Neuropeptides (IBIS), Virgen del Rocío University Hospital, 41013 Seville, Spain

Deadline for manuscript submissions:

**closed (15 June 2023)**

### Message from the Guest Editors

Dear Colleagues,

This Special Issue will highlight target therapies and targetable molecules that could be availed for treatment of Cancer.

The predominant features of cancer include dysregulated cellular proliferation, cell death, immunosuppressive factors, anti-cancer immune responses and angiogenesis leading to growth, invasion and metastases. Diseases that could predispose to cancer include but are not limited to Lynch syndrome, Li-Fraumeni syndrome, human papillomavirus (HPV) infection, Epstein-Barr virus (EBV) infection, *Helicobacter pylori* infection, *Opisthorchis viverrini* infection, Schistosomiasis, chronic diabetes, pancreatitis, ulcerative colitis and Crohn's disease.

Targeted cancer therapies/targetable molecules include but not limited to hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery molecules.

Targetable molecules include but not limited to transcription factors, signal transduction molecules, peptides, kinases, epigenetic regulatory proteins, DNA damage repair enzymes, and proteasomes.





# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI